Mesoblast surges on FDA ‘rare paediatric disease’ designation
Joanna MatherWealth editor
Shares in Australian biopharmaceutical company Mesoblast jumped as much as 25 per cent after the US Food and Drug Administration recognised its cell therapy, Revascor, as a potential breakthrough treatment for heart disease in newborn babies.
The Melbourne-based biotech’s stock price rose to 34¢ on Friday.
Loading...
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles